Sanara MedTech Inc. announces the commercial launch of two new innovative extracellular matrix products from Cook Biotech Inc.


Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.

FORT WORTH, TX / ACCESSWIRE / November 9, 2021 / Sanara MedTech Inc.

Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara”, the “Company”) (NASDAQ: SMTI), a provider of surgical and chronic wound care products and technologies dedicated to improving outcomes for patients, announced the commercial launch of two innovative new products from Cook Biotech Inc.

Zach Fleming, President of Sanara, Surgical, said: “A key part of our long term strategy is to offer our customers more solutions that improve results at a lower overall cost. The products we are launching, in partnership with Cook Biotech, are innovative solutions for patients. We are excited about the opportunity to bring them to market and look forward to continuing to develop our relationship with the Cook Biotech team.

Cook Biotech President Umesh Patel added: “Cook Biotech looks forward to this next step in its partnership with Sanara. The company has an experienced team and is growing rapidly in the surgical wound care market. By partnering with Sanara, Cook Biotech continues its mission of providing transformative medical solutions to improve lives. “

Product overview

STRENGTHEN TRGMT Tissue Repair Graft is a sheet of extracellular matrix (“ECM”) of the small intestinal submucosa (“SIS”). The graft is used for implantation to strengthen soft tissue, has a slim profile, comes in multiple sizes, and can be cut to size to suit the patient’s anatomy. FORTIFY TRG Tissue Repair Graft can be hydrated with sterile saline or autologous body fluids, such as blood, bone marrow aspirate, or blood concentrates such as platelet concentrates. This is an FDA 510 (k) approved and terminally sterilized product.

FORTIFIES FLUIDMT The Extracellular Matrix is ​​an advanced wound care device that features SIS ECM technology in a way that can fill in the irregular shapes and depths of wounds. FORTIFY FLOWABLE Extracellular Matrix is ​​indicated for the treatment of wounds including: partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneling / undermining wounds, surgical wounds (donor / graft sites, post-Mohs surgery, post-laser surgery, podiatry, wound dehiscence), traumatic wounds (abrasions, lacerations, second degree burns and skin tears) and draining wounds. FORTIFY FLOWABLE Extracellular Matrix is ​​supplied sterile and is intended for single use only. It is a 510 (k) licensed product.

The addition of these two innovative products allows Sanara to build on our comprehensive portfolio of surgical and wound care products and is not intended to replace any of our existing CellerateRXs.® Surgical products. When used, both products are considered a supply in connection with the surgical event.

About Sanara MedTech Inc.

With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets and distributes wound and skin care products to physicians, hospitals, clinics and to all post-acute care settings and seeks to offer wound care and virtual consultation in dermatology services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgically Activated Collagen®, FORTIFY TRG “Tissue Repair Graft and FORTIFY FLOWABLE” Extracellular Matrix to the surgical markets as well as the following products to the wound care market: BIAKÃ ?? Â ?? S “Antimicrobial Skin and Wound Cleanser, BIAKÃ ?? Â? ? S “Antimicrobial Gel for Wounds, BIAKÃ ?? Â ?? S” Antimicrobial Solution for Skin and Wound Irrigation and HYCOL “Hydrolyzed Collagen. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve results at a lower overall cost. In addition, Sanara is actively seeking to expand in its six focus areas of wound and skin care for the acute, post-acute and surgical markets. Focus areas are Debridement, Biofilm Removal, Hydrolyzed Collagen, Advanced Biologics, Adjuncts for Negative Pressure Wound Treatment and Oxygen Delivery Systems segment of the health industry. For more information, visit

About Cook Biotech

Cook Biotech Inc. develops and manufactures medical products for tissue repair and regenerative medicine applications using proprietary extracellular matrix (ECM) technologies and processes. Cook Biotech products are marketed and distributed under several brands, including Biodesign®, OASIS® and VIM®. Cook Biotech works with partners and distributors including AxoGen Inc., Aziyo Biologics, Cook Medical Inc., Cormatrix, Katena Products Inc., Keystone Dental Inc., Sanara MedTech Inc. and Smith & Nephew Inc., to develop new products, manufacture and provide technical support. Cook Biotech was established in 1995 and is affiliated with the Cook Group in Bloomington, Indiana. It is located in the Purdue Research Park in West Lafayette, Indiana. For more information, visit

Information on forward-looking statements

Statements in this press release that are not historical facts are “forward-looking statements”, within the meaning and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “anticipate”, “believe”, “contemplate”, “continue” “could”, “estimate”, “‘,”‘ intend to “,”, “,,” plan “,” seek ” , “Should”, “target”, “will” or “would”, or the negative aspects of these terms, variations of these terms or other similar expressions. These forward-looking statements include statements regarding the development of new products. These items involve risks, contingencies and uncertainties such as the uncertainties associated with the development and process of obtaining regulatory approval for new products, the extent of demand for products, market acceptance and requirements. customers, the effect of economic conditions, competition, pricing, ability to consume and integrate acquisitions and other risks, contingencies and uncertainties detailed in documents filed by the Company with the SEC, which could cause results of operations, performance or business plans or actual prospects of the Company differ materially from those expressed or implied by such statements.

All forward-looking statements speak only as of the date on which they are made, and the Company does not undertake to revise these statements to reflect future circumstances or the occurrence of unforeseen events, except as required by laws on applicable securities.

Investor contact:

Callon Nichols, Director of Investor Relations
[email protected]

THE SOURCE: Sanara MedTech Inc.

See the source version on

Leave A Reply

Your email address will not be published.